Reduced uptake of [11C]-ABP688, a PET tracer for metabolic glutamate receptor 5 in hippocampus and amygdala in Alzheimer's dementia by Treyer, Valerie et al.








Reduced uptake of [11C]-ABP688, a PET tracer for metabolic glutamate
receptor 5 in hippocampus and amygdala in Alzheimer’s dementia
Treyer, Valerie ; Gietl, Anton F ; Suliman, Husam ; Gruber, Esmeralda ; Meyer, Rafael ; Buchmann,
Andreas ; Johayem, Anass ; Unschuld, Paul G ; Nitsch, Roger M ; Buck, Alfred ; Ametamey, Simon M ;
Hock, Christoph
Abstract: INTRODUCTION: Metabotropic glutamate receptors play a critical role in the pathogenesis
of Alzheimer’s disease due to their involvement in processes of memory formation, neuroplasticity, and
synaptotoxity. The objective of the current study was to study mGluR5 availability measured by [11
C]-ABP688 (ABP) in patients with clinically diagnosed Alzheimer’s dementia (AD). METHODS: A
bolus-infusion protocol of [11 C]-ABP688 was applied in 9 subjects with AD and 10 cognitively healthy
controls (Controls) to derive distribution volume estimates of mGluR5. Furthermore, we also estimated
cerebral perfusion by averaging early frame signal of initial ABP bolus injection. RESULTS: Subjects
with Alzheimer’s dementia (mean age: 77.3/SD 5.7) were older than controls (mean age: 68.5/SD: 9.6)
and scored lower on the MMSE (22.1/SD2.7 vs. 29.0/SD0.8). There were no overall differences in ABP
signal. However, distribution volume ratio (DVR) for ABP was reduced in the bilateral hippocampus
(AD: 1.34/SD: 0.40 vs. Control: 1.84/SD:0.31, p = .007) and the bilateral amygdala (AD:1.86/SD:0.26
vs. Control:2.33/SD:0.37 p = .006) in AD patients compared to controls. Estimate of cerebral blood flow
was reduced in the bilateral hippocampus in AD (AD:0.75/SD:0.10 vs. Control:0.86/SD:0.09 p = .02).
CONCLUSION: Our findings demonstrate reduced mGluR5 binding in the hippocampus and amygdala
in Alzheimer’s dementia. Whether this is due to synaptic loss and/or consecutive reduction of potential
binding sites or reflects disease inherent mechanisms remains to be elucidated in future studies.
DOI: https://doi.org/10.1002/brb3.1632
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consecutive reduction of potential binding sites or reflects disease inherent mecha-
nisms remains to be elucidated in future studies.
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1  | INTRODUC TION
The	pathology	of	Alzheimer's	disease	can	be	divided	in	accumulation	
of	 aggregated	proteins,	 particularly	extracellular	beta-amyloid	 and	
intracellular	phosphorylated	tau,	losses	of	synapses	and	neurons	and	
reactive	processes	including	activation	of	microglia,	astrocytosis	and	
regenerative	 processes	 of	 undetermined	 significance	 (Duyckaerts,	
Delatour,	&	Potier,	2009).	Beta-amyloid	plaques	and	tau	pathology	
are seen as hallmarks of the disease and are applied for patholog-
ical	staging	(Boluda	et	al.,	2014;	Braak	&	Braak,	1995).	 In	addition,	




tion	at	 the	 synaptic	 level	 as	 reviewed	by	Forner,	Baglietto-Vargas,	
Martini,	Trujillo-Estrada,	&	LaFerla,	2017	(Forner	et	al.,	2017).
One	of	 the	puzzle	stones	being	 involved	 in	synaptic	 toxicity	 in	
AD	is	the	interaction	of	Abeta-pathology	with	metabotropic	gluta-
mate	receptor	5	(mGluR5).	mGluR5	together	with	mGluR1	belongs	
to the subgroup I of metabotropic glutamate receptors which are 
all	 G-protein	 coupled	 receptors.	 Subgroup	 I	 is	 functionally	 linked	











Ca2+ storage in the endoplasmic reticulum and mushroom spine loss 
in	hippocampal	neurons	(Zhang	et	al.,	2015).














compared to nonsmokers and a positive age correlation in putamen 
and	occipital	 lobe	over	 all	 groups	 (Akkus	et	 al.,	 2013).	 In	 the	 indi-
vidual	 subgroups	 of	 smokers	 or	 ex-smokers,	 positive	 correlations	
were also seen in other regions including amygdala. When taking 
into	account	number	or	years	of	smoking	in	the	smoker	group,	only	
putamen remained significant with age as significant covariate. No 

















tures.	 Furthermore,	we	expected	 reduced	perfusion-related	 signal	
of	ABP	in	subjects	with	Alzheimer's	disease,	as	perfusion	correlates	
with	neuronal	activity	and	cognitive	performance,	and	is	known	to	
be	 reduced	 in	 Alzheimer's	 disease	 (Gietl	 et	 al.,	 2015;	 Rostomian,	
Madison,	Rabinovici,	&	Jagust,	2011).
























mirtazapine.	 Further	 exclusion	 criteria	 were	 contraindications	 for	
magnet	resonance	tomography	and	significant	exposure	to	radiation.	
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Two subjects had increased thyroid-stimulating hormone values but 
did not show altered peripheral thyroid hormones.
Neuropsychological	 assessment	 included	 CERAD	 PLUS	
(Thalmann	 et	 al.,	 1997),	 fluency	 tests	 (Regard,	 Strauss,	 &	 Knapp,	
1982)	 (S-words	and	5-point	 test),	 the	German	version	of	Auditory	
Verbal	Learning	test	called	VLMT	(Helmstädter	&	Lux,	2001),	visual	
pair	 learning	 test,	digit	 span,	corsi	block	 forward	and	backward	as	
included	in	the	German	version	of	the	Wechsler	Memory	Scale	re-
vised	version	(Haerting	et	al.,	2000),	trail	making	test	TMT	A	and	B	
(Reitan,	1955),	Stroop's	 test	 (Stroop,	1935),	and	a	test	 to	find	con-
cepts	for	similarities	between	different	symbols	on	cards	 (Kramer)
(Kramer,	1954).
The study was conducted after approval of the ethics commit-
tee of the canton Zurich in accordance with the local law and the 
Declaration	of	Helsinki	(WorldMedicalAssociation,	2008).
2.2 | Manual volumetry of the hippocampus




ter volumes as well as ventricles were summed.
2.3 | PET analysis
All	 participants	 received	 a	 3D	 T1	 anatomical	 scan	 (resolution	
0.5	×	0.5	×	1	mm)	on	a	Philips	Achieva	3T	Scanner.	PET	scans	were	
performed	 using	 standard	 bolus-infusion	 protocol	 (Burger	 et	 al.,	
2010).	 Images	were	 acquired	 dynamically	 over	 60	min	 and	 recon-











clear	 parcellation	 method	 as	 implemented	 in	 Neurotool.	MRI	 and	
PET	 images	 were	 coregistered	 based	 on	 early	 frames	 signal	 (first	
6	min).	Gray–white	matter	segmentation	on	the	MRI	images	was	per-
formed with standard 50% probability. Only gray matter segmented 
regions	in	the	coregistered	PET	image	were	analyzed	to	reduce	po-
tential biases of atrophy. Cortical region of interests were defined 
using	 Hammers	 Maximum	 Probability	 Atlas	 while	 noncortical	 re-
gions were calculated with the deep nuclei parcellation method. 
For	this	study,	a	knowledge	base	of	20	reference	sets	was	selected.	
Regions of interest as calculated by the methods mentioned above 
were	applied	on	PET	and	MRI	images	in	individual	MRI	spaces	and	
were	controlled	individually	and	adapted	if	necessary	by	an	expert	
in imaging processing. Individual cortical regions as defined by the 
atlas were averaged between hemispheres and lobes to test for gen-
eral differences in the lobes. White matter and ventricular regions 
were calculated in order to appropriately apply volume of interest 
(VOI)-based	 partial	 volume	 correction	 (geometric	 transfer	 matrix	






and secondly the volume of interest-based partial volume correction 
ensure	better	quantification	and	correction	of	partial	volume	effects	
especially due to atrophy for all regions.
For	distribution	volume	estimates	 (DVR),	 late	 frame	PET	signal	
(45–60	min)	was	 averaged	 over	 the	VOIs	 and	 divided	 by	 cerebel-
lar	gray	matter	values.	Perfusion-related	signal	was	extracted	from	
early	frame	data	(first	3	min)	and	divided	by	cerebellar	signal	for	nor-
malization	 to	 control	 for	 variations	 in	 injected	 dose	 (Burger	 et	 al.,	
2010).	As	mentioned	above,	not	all	regions	available	in	the	templates	
were used for analysis. Only bilaterally averaged region assessments 
were used to test for group differences in the cortical regions as 
no	hypothesis	on	differences	within	 lobes	was	 set.	Therefore,	 the	
VOIs	 in	frontal,	 temporal,	parietal,	and	occipital	 lobe	were	merged	
within	the	lobes	(resulting	in	4	regions).	The	remaining	regions	were	
taken as defined in the hammers atlas and the parcellation method 
mentioned above and only averaged between sides. This results in 
following	bilateral	 regions:	 insula,	anterior	cingulate,	posterior	cin-
gulate,	 thalamus,	 putamen,	 caudate,	 amygdala,	 and	 hippocampus	
(additional	8	regions).	A	total	of	12	regions	was	taken	into	statistical	
analysis.
Due to the differences in hippocampal volume additionally to the 
volume	of	interest-based	approach	for	partial	volume	correction,	a	
different	 MRI-based	 approach	 was	 selected	 for	 methodological	
reasons	in	addition.	We	used	the	Muller-Gartner	method	according	
PMOD	standard	implementation	for	gray	matter	spill-out	and	white	
matter	 spill-in	 on	 the	 dynamic	 PET	 images	 (Muller-Gartner	 et	 al.,	
1992).	We	used	 the	 results	of	 these	methods	primarily	 to	 test	 for	




we	 chose	 not	 to	 correct	 for	multiple	 comparisons.	 All	 variable	 of	




covariates,	 general	 linear	model	 univariate	 procedures	were	 used.	
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Tests	were	performed	two	sided.	To	check	for	potential	biases,	also	
nonpartial volume corrected regional values were statistically tested 
for significance and showed similar effects.
3  | RESULTS
Please note that all p values are reported uncorrected.
3.1 | Confirmation of perfusion and volumetric 
differences between AD and control group










difference	 is	 seen	 in	 the	 hippocampus,	 and	 a	 typical	 region	 is	 af-




erage	 PET,	 respectively,	 through	 VBM	 processing	 generated	 tem-
plate image.
Comparing both groups with regard to manual hippocampal 
volumetry,	we	see	significant	differences	(corrected	for	total	brain	

















3.3 | Regional differences in mGluR5 binding in 
bilateral Hippocampus and Amygdala
A	potential	 overall	 effect	 of	 differences	 between	both	 groups	with	


















on	MRI-based	partial	 volume	corrected	 images	 (MG	PVC)	demon-
strating	in	both	cases	(noPVC	and	MG	PVC)	the	effect	in	the	hippo-
campus	(t(17)	=	−2.8,	p = .012 on uncorrected images and t(17)	=	−2.6,	
p	=	.017	on	MG	PVC),	revealing	the	robustness	of	the	results.












this region. This patient had the lowest relative volume of anterior hip-
pocampus. The difference between groups remained significant also 
when	excluding	this	case	in	the	t test analysis of hippocampal values 
(t(17)	=	−2.85,	p = .012 instead of t(17)	=	−3.04,	p = .007 in PVC corrected 
t	test).
For	 further	 evaluation	 of	 hippocampal	 and	 amygdala	 group	
differences,	an	univariate	analysis	of	variance	with	the	covariate	
age	 and	 depression	 (MADRS	 score)	 was	 performed	 in	 addition.	
The	 model	 was	 significant	 (Hippocampus:	 F(3,18)	 =	 3.9,	 p = .031 
partial	eta	squared	 (PES)	=	0.44,	Amygdala:	F(3,18)=	4.7,	p	=	 .016,	
PES	=	0.49.)	The	factor	group	as	well	as	the	two	covariates	were	
not	significant.	 In	 the	hippocampus,	we	see	 following	results	 for	
Group:	F(3,18)	=	2.25,	p	=	 .155,	PES	=	0.13,	 for	age:	F(3,18)	=	0.86,	
p	 =	 .368,	 PES	 =	 0.05	 and	 for	 MADRS:	 F(3,18)	 =	 1.28,	 p	 =	 .277,	
PES	=	0.08.
In	 the	 Amygdala,	 the	 following	 results	 were	 found	 for	 Group:	
F(3,18)	=	2.48,	p	=	 .136,	PES	=	0.14,	 for	age:	F(3,18)	=	0.35,	p	=	 .564,	
PES	=	0.02	and	for	MADRS:	F(3,18)	=	2.92,	p	=	.108,	PES	=	0.16.
3.4 | Reduced estimate for cerebral perfusion in 
bilateral hippocampus
Estimate	 for	 cerebral	 perfusion	 was	 reduced	 in	 the	 hippocampus	
(t(17)	=	−2.56,	p	=	.020)	but	not	in	the	amygdala	(t(17)	=	−1.28,	p	=	.22).
Including	age	and	MADRS	as	covariate	in	the	univariate	model,	
no significant effects are remaining in hippocampus: F(3,18)	=	2.8,	
p	=	 .076	Partial	Eta	Squared	=	0.36,	Group:	F(3,18)	=	3.3,	p	=	 .09,	
PES	 =	 0.18;	 age	 F(3,18)	 =	 1.0,	 p	 =	 .329,	 PES	 =	 0.06;	 MADRS:	




3.5 | Association of perfusion estimates and 
mGluR5 binding with cognitive measures
Correlations with neuropsychological variables were conducted 
only	in	AD	patients	for	the	hippocampus,	the	region	a	priori	related	
to	 cognitive	 function(Guzman-Velez,	 Warren,	 Feinstein,	 Bruss,	 &	
Tranel,	2016).
TA B L E  1   Description of the study population and comparisons between groups
Parameter










Age .07 68.5	(SD	9.6) 77.3	(SD	5.7) .028*  
MMSE .005* 29	(SD	0.8) 22.1	(SD	2.7)  .000*
Education	in	years .114 13.7	(SD	2.8) 11.7	(SD	1.8)	N = 7 .120  
Gender	(f/m)  7/3 6/3   
MADRS .016* 2.8	(4.0) 6.2	(2.2)  .028*
Boston	Naming	total <.001* 14.8(SD	0.4)	(median) 12.1	(SD	2.5)	(median)  .008*
S-word	total .200 28.7	(SD	8.7) 17.6	(SD	8.2) .011*  
5-point total .200 25.9	(SD	8.0) 17.0	(SD	5.5) .012*  
WRD recall .002* 8.9	(SD	1.0) 1.6	(SD	2.6)  .000*
WRD recognition .000* 9.9	(SD	0.3) 7.6	(SD	2.5)  .022*
Digit	Span	forward .076 7.1	(SD	1.4) 5.8	(SD	1.9)  .053
Digit	Span	backward .016* 5.8	(SD	1.6) 4.3	(SD	1.7)  .053
Corsi	Block	forward .011* 7.8	(1.3) 6.1	(SD	2.4)  .113
Corsi	Block	backward .002* 6.8	(SD	8.3) 5.3	(SD	2.0)  .136
Kramer .200 3.7	(SD	1.1) 2.2	(SD	1.2) .011*  
WMS	visual	pairs	learning .200 12.8	(SD	2.7) 4.9	(SD	3.7)	1	did	not	
perform test
.000*  















*indicates significant values p< .05. 
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Global	 cognition	measured	with	MMSE	 score	was	 associated	
with	 perfusion	 estimate	 (Spearman	 ρ	 =	 0.809,	p	 =	 .008)	 but	 not	
with	mGluR5	 binding	 as	 assessed	 by	DVR	 (Spearman	 ρ	 =	 0.655,	
p	=	.055).












We	 report	 results	 on	 mGluR5	 ([11C]-688ABP)	 PET	 in	 a	 popula-
tion	 of	 subjects	 with	 Alzheimer's	 disease.	 To	 our	 knowledge,	 this	
is	the	first	publication	on	mGluR5	 imaging	 in	human	with	ABP688	
in	Alzheimer's	disease.	We	 identified	 lower	mGluR5	binding	 in	the	
bilateral hippocampus and bilateral amygdala. The findings were 












binding and overall binding was not different between groups.




4.1 | Reduction in mGluR5 binding may be due 




hippocampus and the amygdala.
Indeed,	we	also	observe	a	reduced	estimate	for	cerebral	blood	
flow in the hippocampus. Cerebral blood flow is coupled to cerebral 
metabolism	 (Paulson,	Hasselbalch,	Rostrup,	Knudsen,	&	Pelligrino,	
2010)	and	could	serve	as	an	estimate	for	synaptic	integrity	(Rocher,	
F I G U R E  2  Normalized	and	averaged	mGluR5	DVR	images	of	
both	groups.	(a)	shows	the	axial	images	of	the	healthy	control	group	
and	(b)	the	images	of	the	AD	group
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Chapon,	Blaizot,	Baron,	&	Chavoix,	2003).	Our	 findings	are	 in	 line	




to age-matched wild-type mice. The authors suspected this to be 
due	to	excitotoxicity-mediated	synapse	loss	as	this	model	develops	
loss	 of	 neurons	 and	 a	 reduction	 of	 several	 synaptic	 markers	 (Lee	
et	al.,	2018).	In	a	longitudinal	study,	the	authors	found	that	in	5xFAD	














blotting	 and	 immunofluorescence	 in	 the	 transgenic	 animals	 (Fang	
et	 al.,	 2017).	 In	 this	model,	 extracellular	 amyloid	deposition	 starts	












4.2 | Reduction in mGluR5 binding as a potential 
regulatory mechanism
On	the	other	hand,	 it	 is	striking	that	we	observe	reduced	mGluR5	
binding specifically in the hippocampus and the amygdala re-




These regions that are highly connected and play an important 
role	in	memory	formation	and	in	the	regulation	of	emotions	(Janak	&	
Tye,	2015;	Kitamura	et	al.,	2017;	Leal	et	al.,	2017).	Thus,	it	is	tempt-




functional for memory formation under physiological conditions. It 
has been shown that metabotropic glutamate receptor-dependent 
long-term	depression	was	critical	for	successful	aging	in	rats	(H.	K.	
Lee,	Min,	Gallagher,	&	Kirkwood,	 2005).	 Furthermore,	 positive	 al-
losteric	modulators	of	mGluR5	were	associated	with	enhanced	cog-
nitive	 performance	 in	 preclinical	models	 (Balschun,	 Zuschratter,	&	
Wetzel,	2006;	Uslaner	et	al.,	2009).
However,	in	a	situation	like	Alzheimer's	disease	where	synapses	
are	 lost,	mechanisms	 of	 long-term	 depression	 (LTD)	may	 be	 addi-
tionally	 detrimental	 to	memory	 function.	 Indeed,	mGluR5	was	 in-
volved	in	Abeta-monomer	dependent	LTD	(Chen	et	al.,	2013).	Most	







DVR delta delta % t-value (df 17) p value 95% CI
Frontal	lobe 2.03	(0.29) 2.02	(0.21) −0.016 −0.8 −0.14 .890 −0.26–0.23
Temporal lobe 1.99	(0.26) 1.98	(0.19) −0.008 −0.4 −0.08 .940 −0.23–0.21
Parietal lobe 2.06	(0.27) 2.04	(0.23) −0.018 −0.9 −0.16a  .875 −0.26–0.22
Occipital lobe 1.9	(0.21) 1.97	(0.2) 0.07 3.7 0.74a  .469 −0.13–0.27
Insula 1.84	(0.24) 1.93	(0.22) 0.091 4.9 0.85a  .406 −0.13–0.32
Anterior	Cingulum 2	(0.28) 1.96	(0.26) −0.044 −2.2 −0.35a  .732 −0.31–0.22
Posterior Cingulum 1.77	(0.22) 1.78	(0.17) 0.017 1.0 0.19 .851 −0.17–0.20
Thalamus 1.37	(0.13) 1.37	(0.1) 0.004 0.3 0.07 .946 −0.11–0.12
Putamen 1.81	(0.25) 1.89	(0.21) 0.078 4.3 0.72a  .479 −0.15–0.30
Caudate 1.87	(0.4) 1.74	(0.46) −0.131 −7.0 −0.67 .514 −0.55–0.28
Amygdala 2.33	(0.37) 1.86	(0.26) −0.472 −20.3 −3.16 .006 −0.79	to	−0.16
Hippocampus 1.84	(0.31) 1.34	(0.4) −0.501 −27.2 −3.04 .007 −0.85	to	−0.15
aLevene's	test	significant,	variances	considered	as	nonhomogenous.	
bBold	values	are	statiscally	significants.	







So	 it	may	well	 be	 that	 a	 downregulation	 of	mGluR5	 occurs	 in	
Alzheimer's	disease	and	this	may	be	a	compensatory	process.
However,	in	the	AD	group,	we	only	identify	positive	associations	





compensatory	mechanism.	Saying	 this,	 it	 is	clear	 that	our	data	are	
derived	from	just	nine	AD	subjects	and	warrant	replication.
4.3 | Differences in age and depression scores 
do not account for the observed effects
As	age	and	depression	scores	were	not	balanced	among	groups,	we	in-




sociation with depression in this region in addition to the group effect.
A	study	focusing	on	a	comparison	of	late-life	depression	and	con-
trols	did	not	find	differences	in	amygdala	binding(DeLorenzo	et	al.,	
2015).	 Also,	mGluR5	binding	 did	 not	 change	with	 age	 in	most	 re-
gions.	 A	 positive	 association	 between	mGluR5	 binding	 and	 age	 in	
the	right	amygdala	went	in	the	opposite	direction	(J.	M.	DuBois	et	al.,	




4.4 | Methodological considerations and limitations
This	is	an	exploratory	study	with	a	low	sample	size,	which	limits	the	
generalizability	of	our	results.	Negative	findings	may	be	solely	due	




between patients and controls.
Both	groups	were	not	age	matched,	and	the	AD	group	was	older	
than	 the	 controls.	 The	 participants	 in	 the	 AD	 group	 also	 showed	
higher	 depression	 scores	 compared	 to	 the	 healthy	 controls.	 Both	
factors have been shown to be in some studies associated with 
mGluR5	binding	(Deschwanden	et	al.,	2011).	Statistically,	we	intro-
duced both variables as covariates.
Comparisons	were	not	 corrected	 for	multiple	 testing,	which	 in	
our	eyes	would	have	been	 inappropriate	 for	an	exploratory	 study.	
For	discussion	on	 this	 topic,	 please	 see	Althouse,	 2016	 (Althouse,	
2016).	As	 the	mGluR5	binding	differences	 in	amygdala	and	hippo-






subtle differences in smoking habits between the groups. Reductions 
in	 mGluR5	 binding	 in	 smokers	 and	 ex-smokers	 are	 widespread	
throughout	the	cortex	and	not	specific	for	the	hippocampus	and	the	
amygdala	(Akkus	et	al.,	2013).	We	therefore	consider	it	very	unlikely	
that the observed results are due to differences in smoking habits.
Next,	in	the	Alzheimer's	disease	group,	six	subjects	were	on	cho-
linesterase inhibitors and 4 subjects received escitalopram and one 
mirtazapine.	mGluR5	expression	was	 found	minimally	upregulated	
in neurons and astrocytes of adult mice after chronic treatment with 
the	 SSRI	 fluoxetine,	 so	 a	 putative	 effect	 of	 antidepressant	 medi-
cation	would	point	 in	the	opposite	direction	of	our	findings	(Hertz	
et	 al.,	 2014).	However,	due	 to	 the	close	 relationship	between	glu-
tamatergic	and	serotonergic	system	(Pehrson	&	Sanchez,	2014),	we	
cannot	entirely	exclude	an	effect	of	the	antidepressant	medication	




We have only included estimates of perfusion to estimate po-
tential effects of synaptic density and neuronal loss. The inverse 
correlation of the perfusion estimate in the hippocampus with the 
MMSE	 score	 points	 to	 a	 utility	 of	 this	measurement,	 as	 this	 rela-
tionship	was	observed	in	FDG-PET	studies	as	well	(Alavi,	Newberg,	
Souder,	&	Berlin,	1993;	Rostomian	et	al.,	2011).
We used the established bolus-infusion paradigm for this study 
(Burger	et	al.,	2010)	but	these	methods	need	cerebellar	gray	matter	
as reference region which does limit the results to the assumption 
that no differences in binding between both groups are present in 
this region at this stage of disease.
Furthermore,	our	results	are	not	generalizable	to	mechanisms	in	
preclinical	or	prodromal	Alzheimer's	disease,	as	our	AD	Group	has	
high variability in clinical scores and does not cover the complete 
spectrum of the disease.
5  | CONCLUSION
Using	ABP,	we	 could	 identify	 a	 reduction	 in	mGluR5	binding	 esti-
mated	 by	 ABP	 in	 Alzheimer's	 dementia	 in	 the	 hippocampus	 and	
the	amygdala,	which	could	be	due	 to	either	 losses	 in	postsynaptic	
binding	sites	or	adaptive	processes	 in	Alzheimer's	disease.	Further	
studies should ideally include direct markers of synaptic density to 
disentangle	the	mechanisms	behind	mGluR5	binding	loss.
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